Context The association between the gut microbiota and thyroid cancer remains controversial. Objective We aimed to systematically investigate the interactive causal relationships between the abundance and metabolism pathways of gut microbiota and thyroid cancer. Methods We leveraged genome-wide association studies for the abundance of 211 microbiota taxa from the MiBioGen study (N = 18,340), 205 microbiota metabolism pathways from the Dutch Microbiome Project (N = 7738), and thyroid cancer from the Global Biobank Meta-analysis Initiative (N cases = 6699 and N participants = 1,620,354). We performed a bidirectional Mendelian randomization (MR) to investigate the causality from microbiota taxa and metabolism pathways to thyroid cancer, and vice versa. We performed a systematic review of previous observational studies and compared MR results with observational findings. Results Eight taxa and twelve metabolism pathways had causal effects on thyroid cancer, where RuminococcaceaeUCG004 genus (P = 0.001), Streptococcaceae family (P = 0.016), Olsenella genus (P = 0.029), ketogluconate metabolism pathway (P = 0.003), pentose phosphate pathway (P = 0.016), and L-arginine degradation II in AST pathway (P = 0.0007) were supported by sensitivity analyses. Conversely, thyroid cancer had causal effects on three taxa and two metabolism pathways, where the Holdemanella genus (P = 0.015) was supported by sensitivity analyses. The Proteobacteria phylum, Streptococcaceae family, Ruminococcus2 genus, and Holdemanella genus were significantly associated with thyroid cancer in both the systematic review and MR, while the other 121 significant taxa in observational results were not supported by MR. Discussions These findings implicated the potential role of host-microbiota crosstalk in thyroid cancer, while the discrepancy among observational studies calls for further investigations.
Identifying factors affecting lifespan, including genes or proteins, enables effective interventions. We prioritized potential drug targets and provided insights into biological pathways for healthy longevity by integrating Mendelian randomization, cohort, and experimental studies. We identified causal effects of tissue‐specific genetic transcripts and serum protein levels on three longevity outcomes: the parental lifespan, the top 1% and 10% extreme longevity, utilizing Mendelian randomization and multi‐traits colocalization, combining the latest genetics data of gene expression (eQTLGen and GTEx) and proteomics (4746 proteins from five studies). We then evaluated associations of these potential genetic targets with mortality risk and life expectancy in the UK Biobank cohort. We performed in vitro cellular senescence experiments to confirm their effects. Fourteen plasma proteins and nine transcripts in whole blood had independent causal effects on longevity, where a cascading effect of both the tissue‐specific transcripts and plasma proteins of LPA, PDAP1, DNAJA4, and TMEM106B showed negative effects on longevity. PDAP1 (PDGFA‐associated protein 1) with the strongest genetic evidence might reduce lifespan by modifying sex hormones, adiposity, and epigenetic aging acceleration. In the prospective cohort, blood PDAP1 levels were significantly associated with higher all‐cause mortality and more years of loss. In vitro, cellular senescence is accompanied by upregulation of PDAP1 expression. Exogenous PDAP1 stimulation accelerates cellular senescence while the deficiency of PDAP1 attenuates replicative senescence. This study facilitates the discovery of potential drug targets and provides a broader understanding of the biological processes of longevity, where PDAP1 emerged as a star for modifying human lifespan.
Context: The association between gut microbiota and thyroid cancer remains controversial. Objective: We aimed to systematically investigate the interactive causal relationships between the abundance and metabolism pathways of gut microbiota, and thyroid cancer. Methods: We leveraged the genome wide association studies for the abundance of 211 microbiota taxa from the MiBioGen study (N=18,340); 205 microbiota metabolism pathways from the Dutch Microbiome Project (N=7738); and thyroid cancer from the largest meta-analysis of Global Biobank Meta-analysis Initiative (N cases=6699 and N participants=1,620,354). We performed a bidirectional Mendelian randomization (MR) to investigate the causality from microbiota taxa, metabolism pathways to thyroid cancer, and vice versa. We did a systematic review of the previous observational studies and compared MR results with observational findings. Results: Eight taxa and twelve metabolism pathways had causal effects on thyroid cancer, where RuminococcaceaeUCG004 genus ( P =0.001), Streptococcaceae family ( P =0.016), Olsenella genus ( P =0.029), ketogluconate metabolism pathway ( P =0.003), pentose phosphate pathway ( P =0.016), and L-arginine degradation II in AST pathway ( P =0.0007) were supported by sensitivity analyses. Conversely, thyroid cancer had causal effects on three taxa and two metabolism pathways, where Holdemanella genus ( P =0.015) was supported by sensitivity analyses. The Proteobacteria phylum, Streptococcaceae family, Ruminococcus2 genus, and Holdemanella genus were significantly associated with thyroid cancer in both systematic review and MR, while other 121 significant taxa in observational results were not supported by MR. Discussions: These findings implicated the potential role of host-microbiota crosstalk in thyroid cancer, while the discrepancy among observational studies called for further investigations.
Background: Polygenic risk scores (PRS) can provide a proxy for genetic liability to smoking- and alcohol-related behaviors. If these behavior-associated PRS can also predict the risk or survival of head and neck squamous cell carcinoma (HNSCC), then such PRS can provide motivation for behavioral modification during counseling by associating behavior with its consequences.Methods: Based on the VOYAGER Consortium of 3,254 controls and 5,538 HNSCC cases, where 3,194 were HPV-positive, we constructed PRS for multiple smoking and alcoholic metrics, using summary statistics from GSCAN. We evaluated the HPV-stratified HNSCC risk by logistic regression, overall survival by Cox models comparing different percentile strata of PRS and compared these results to observed behaviors.Findings: Each higher PRS predicted greater corresponding smoking and alcohol use behaviors. For HPV-positive diseases, higher PRS for smoking initiation and alcoholic drinks-per-week predicted increased HNSCC risk. Similarly, higher PRS for smoking initiation, cigarettes-per-day, smoking cessation, and alcoholic drinks-per-week each predicted higher HPV-negative HNSCC risk. For overall survival, higher PRS of smoking initiation (HR = 1.08, P=0.017) and alcoholic drinks-per-week (HR=1.14, P=2.66×10-4) predicted poorer prognosis in HPV-positive cases. Illustrative models showed similar results for a genetic counseling purpose. Each PRS predicted its corresponding observed behavior which mediated part of the associations (7.30%-54.6%) between PRSs and HNSCC risk or survival.Interpretation: Smoking- and alcohol-related PRS predicted observed behaviors, greater HNSCC risk and poorer overall survival. These findings support integrating genetic liability with clinical factors to refine counseling strategies for behavior modification.
2 July 2026 in Cancer Epidemiology, Biomarkers & Prevention
Background: Cholesterol pathways may influence head and neck squamous cell carcinoma (HNSCC) progression, but evidence on prognosis is inconsistent. We used Mendelian randomization (MR) to test whether genetically proxied inhibition of major LDL-C–lowering drug targets and circulating lipid traits affects overall survival (OS) in HPV-positive and non-HPV driven HNSCC. Methods: We proxied lifelong LDL-C lowering using 55 cis-acting SNPs in HMGCR, NPC1L1, PCSK9, and LDLR from the updated 2021 Global Lipids Genetics Consortium, and instrumented circulating lipid traits. Two-sample MR estimated effects on OS in 4,869 multi-centre HNSCC cases (1,291 HPV-positive; 3,578 non-HPV driven) using minimally adjusted Cox models. Sensitivity analyses additionally adjusted for tumour stage and treatment, assessed collider bias using an external HNSCC incidence GWAS, and examined between-centre heterogeneity and colocalization. Results: Using the updated GLGC 2021 instruments, genetically proxied HMGCR inhibition showed a directionally protective but non-significant association with OS in HPV-positive oropharyngeal HNSCC in the primary analysis (IVW HR=0.19, 95% CI 0.03–1.18; P=0.08), with directionally concordant weighted median results. No corresponding protective association was observed for HMGCR in non-HPV-driven disease (IVW HR=1.68, 95% CI 0.78–3.63; P=0.19). No clear evidence of association was observed for NPC1L1, PCSK9, LDLR, or circulating lipid traits in either HPV stratum. Colocalization did not support a shared causal variant. Conclusions: These analyses provide suggestive evidence that genetically proxied HMGCR inhibition may influence survival in HPV-positive oropharyngeal HNSCC. Impact: HMGCR-related pathways may be relevant to prognosis in HPV-positive oropharyngeal HNSCC, whereas clear survival effects of other cholesterol-lowering targets were not supported.